Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw some unusual options trading activity on Wednesday. Stock traders acquired 10,217 put options on the company. This represents an increase of 70% compared to the typical volume of 6,015 put options.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CMPS. Compass Point set a $25.00 price objective on Compass Pathways in a report on Tuesday, July 7th. Wall Street Zen lowered Compass Pathways from a “sell” rating to a “strong sell” rating in a report on Monday. Stifel Nicolaus raised their price target on Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, BTIG Research upped their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and an average price target of $23.36.

Institutional Investors Weigh In On Compass Pathways

Institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank increased its holdings in Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the period. Nantahala Capital Management LLC lifted its holdings in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares during the period. Ameriprise Financial Inc. acquired a new position in Compass Pathways during the 3rd quarter worth about $6,926,000. Orbimed Advisors LLC acquired a new position in Compass Pathways during the 1st quarter worth about $6,363,000. Finally, Siren L.L.C. bought a new stake in shares of Compass Pathways in the 4th quarter valued at about $6,900,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Price Performance

Compass Pathways stock opened at $14.61 on Thursday. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $2.02 billion, a PE ratio of -3.16 and a beta of 2.50. Compass Pathways has a 12 month low of $4.40 and a 12 month high of $15.40. The stock has a 50-day moving average price of $13.02 and a two-hundred day moving average price of $10.00.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Analysts expect that Compass Pathways will post -1.26 EPS for the current year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.